HCPCS (current)
J3590
NOC / invoice; no permanent J-code
Phase 1
Identify what you're billing
Confirm Lyfgenia vs Casgevy (mechanism + boxed warning) and vs AAV gene therapies; confirm SCD genetic status, recurrent VOC history, and QTC eligibility before scheduling apheresis. Lyfgenia has NO TDT indication.
Gene therapy class — Lyfgenia (lentiviral HSC) vs Casgevy (CRISPR HSC) vs Zolgensma / Hemgenix / Roctavian (AAV in-vivo) FDA labels verified May 2026
Five FDA-approved gene therapies in the CareCost catalog, four mechanisms, two billing pathway families. Don't confuse them at the claim layer.
Gene therapy is no longer a single product class. The CareCost catalog now indexes five FDA-approved gene therapies, which fall into two operationally distinct billing families:
- Ex vivo cell-based gene therapies — autologous HSCs collected by apheresis, modified at a manufacturing facility (lentiviral transduction or CRISPR/Cas9 editing), and reinfused after myeloablative conditioning. Multi-stage encounter spanning apheresis, manufacturing, conditioning, infusion, and engraftment monitoring. Lyfgenia (this page) and Casgevy are the SCD examples; CAR-T therapies (Kymriah, Yescarta, Breyanzi, Carvykti, Abecma) share this multi-stage shape but use lymphodepletion rather than myeloablation.
- In vivo AAV-based gene therapies — a single IV infusion of an AAV vector that delivers a transgene to target tissues. Single-encounter billing (one J-code + one admin CPT). The CareCost examples are Zolgensma (J3399, AAV9, pediatric SMA), Hemgenix (J1411, AAV5, hemophilia B), and Roctavian (J1412, AAV5, hemophilia A).
| Lyfgenia (J3590) | Casgevy (J3590) | Zolgensma (J3399) | Hemgenix (J1411) | Roctavian (J1412) | |
|---|---|---|---|---|---|
| Mechanism | Lentiviral (BB305) + bA-T87Q transgene (ex vivo) | CRISPR/Cas9 edit of BCL11A enhancer (ex vivo) | AAV9 + SMN1 transgene (in vivo) | AAV5 + FIX-Padua transgene (in vivo) | AAV5 + FVIII-SQ transgene (in vivo) |
| Cell vs vector | Autologous HSC product | Autologous HSC product | AAV vector | AAV vector | AAV vector |
| Indication | SCD (vaso-occlusive events); NO TDT | SCD (recurrent VOCs); TDT | Pediatric SMA (bi-allelic SMN1) | Adult hemophilia B (FIX ≤ 2%) | Adult hemophilia A (FVIII ≤ 1%) |
| Age (label) | ≥ 12 yr | ≥ 12 yr | < 2 yr | Adult | Adult |
| Conditioning | Busulfan myeloablation (4 d) | Busulfan myeloablation | None (in vivo) | None (in vivo) | None (in vivo) |
| Hospitalization | ~30–45 d inpatient | ~30–45 d inpatient | Planned short admission | Outpatient infusion | Outpatient infusion |
| Pre-treatment immune gate | None (autologous, no AAV) | None (autologous, no AAV) | Anti-AAV9 antibody ≤ 1:50 | Anti-AAV5 NAb (label) | Anti-AAV5 NAb (label) |
| Boxed warning | YES — hematologic malignancy | No boxed warning | Acute liver injury / failure | No (W&P: hepatic, immunogenicity) | No (W&P: hepatic) |
| HCPCS | J3590 NOC | J3590 NOC | J3399 permanent | J1411 permanent | J1412 permanent |
| Product list (one-time) | ~$3.1M | ~$2.2M | ~$2.125M | ~$3.5M | ~$2.9M |
| Total course (incl. facility) | ~$3.6M–$4.5M | ~$2.7M–$3.5M (admission) | ~$2.2M–$2.5M (admission) | ~$3.6M (infusion clinic) | ~$3.0M (infusion clinic) |
| Outcomes-based contracts | Common (CMS CGT Model) | Common (CMS CGT Model) | Common | Common | Common |
Lentivirus vs CRISPR — why the boxed warning matters for billers. At the operational
billing level, Lyfgenia and Casgevy look almost identical: same autologous apheresis collection, same
~3–6 month manufacturing window, same busulfan myeloablation, same HSC infusion, same engraftment
monitoring. The critical differences are (1) boxed warning: Lyfgenia carries an FDA boxed
warning for hematologic malignancy (myeloid malignancies reported; the BB305 lentiviral vector integrates
semi-randomly into the host genome, carrying a small theoretical insertional-mutagenesis risk that combines
with busulfan genotoxicity); Casgevy does not. (2) Mechanism: Lyfgenia adds a transgene
encoding a modified β-globin (bA-T87Q) that polymerizes less than HbS, producing the anti-sickling
hemoglobin variant HbA-T87Q. Casgevy disrupts BCL11A (a transcriptional repressor of HbF), restoring fetal
hemoglobin. (3) Indication scope: Lyfgenia is SCD-only; Casgevy covers SCD and
transfusion-dependent β-thalassemia (TDT). (4) Payer preferences: most payers cover both
products, but a meaningful share of plans prefer Casgevy at PA because of the cleaner safety label; document
the clinical rationale for Lyfgenia-specifically (e.g., bA-T87Q mechanism preference, clinical-team
familiarity, prior bluebird relationships) in the PA packet.
Once-per-lifetime constraint. Payers universally limit coverage to one autologous ex vivo
modified HSC therapy per patient lifetime. A patient who has received Lyfgenia is not eligible for Casgevy
(and vice versa). The patient is also generally not eligible for additional HSCT for SCD, allogeneic or
otherwise, except in case of engraftment failure. Document the once-per-lifetime determination, the
product-selection rationale (Lyfgenia vs Casgevy), and the long-term follow-up plan (including the
hematologic-malignancy REMS enrollment for Lyfgenia) in the PA packet.
Dosing & unit math FDA label verified May 2026
From the FDA-approved Lyfgenia prescribing information (BLA 125788; current label rev. Apr 7, 2026). Unit-of-billing is the patient-specific HSC product (one J-code event); the underlying physical dose is weight-based CD34+ cell count.
Approved indication
- Sickle cell disease (SCD) in patients ≥ 12 years with a history of vaso-occlusive events. Genetic confirmation HbSS / HbSC / HbS–β-thalassemia. FDA approval December 8, 2023 (BLA 125788) — same day as Casgevy SCD approval.
- Lyfgenia is NOT approved for transfusion-dependent β-thalassemia (TDT). Use Casgevy for the TDT indication. Patients with TDT who attempt Lyfgenia will be denied on the indication criterion.
Weight-based dosing
| Element | Value | Notes |
|---|---|---|
| Minimum dose | 3 × 10⁶ CD34+ cells/kg | Per FDA label; lower doses are not infused (insufficient engraftment risk) |
| Typical dose | 4–20 × 10⁶ CD34+ cells/kg | Driven by apheresis yield, manufacturing yield, and transduction efficiency |
| Transduction target | BB305 lentiviral vector encoding modified β-globin (bA-T87Q) | VSV-G pseudotyped, self-inactivating lentiviral vector; semi-random integration into host HSC genome; produces anti-sickling HbA-T87Q in erythroid lineage |
| Product form | Cryopreserved suspension | DMSO-containing cryopreservation medium; thawed at bedside; patient-identified bag at every step |
| Infusion duration | Per institutional HSCT protocol | Typically over 30–60 min via central line; vital signs per HSCT standard |
| Total cycles | 1 (one-time) | Per patient lifetime; not repeatable per label and payer policy |
| Age (label) | ≥ 12 years | SCD only |
Worked example — 60 kg adolescent with HbSS sickle cell disease and recurrent vaso-occlusive events
# Calculate target dose
Weight: 60 kg
Minimum target: 3 × 10⁶ CD34+/kg × 60 kg = 1.8 × 10⁸ CD34+ cells total
Typical infused: 6–10 × 10⁶ CD34+/kg = 3.6–6.0 × 10⁸ cells total
# Multi-stage encounter timeline
Day −180 to −120: SCD diagnosis confirmation, VOC documentation, HSCT eligibility eval, fertility counseling, hematologic-malignancy REMS enrollment
Day −120: Apheresis HSC collection (outpatient, QTC) — CPT 38206 / 0540T
Day −120 to −7: ex vivo lentiviral transduction at bluebird facility (~3–6 months)
Day −7 to −3: Busulfan myeloablative conditioning — J0594 or NOC
Day 0: Autologous HSC infusion — HCPCS J3590 + CPT 38241
Day +14 to +28: Neutrophil engraftment (ANC ≥ 500 × 3 days)
Day +30 to +45: Platelet engraftment, discharge planning
Day +60 to +365: Outpatient follow-up; HbA-T87Q / HbA / Hb electrophoresis monitoring
Months 6, 12, 24, 60: Outcomes milestone reporting (bluebird Patient Services / payer OBA)
Year 1–15: Lifelong CBC w/diff hematologic-malignancy surveillance (BOXED warning)
# Billing claim line (HSC infusion encounter)
Drug: J3590 · 1 unit per patient-specific HSC product (NOC; per-treatment, not per cell)
Admin: CPT 38241 (Hematopoietic progenitor cell transplant; autologous)
Apheresis (prior encounter): CPT 38206 (HSC apheresis; autologous) or 0540T (category III for HSC therapy product, autologous transplantation)
Conditioning: J-code for high-dose busulfan (J0594) or NOC
# Course cost (manufacturer WAC + facility)
Lyfgenia product (WAC): ~$3,100,000 (one-time)
Apheresis + manufacturing handling: ~$50,000–$100,000
Busulfan conditioning + 30–45 d inpatient: ~$400,000–$900,000+
Total course estimate: ~$3.6M–$4.5M
Weight: 60 kg
Minimum target: 3 × 10⁶ CD34+/kg × 60 kg = 1.8 × 10⁸ CD34+ cells total
Typical infused: 6–10 × 10⁶ CD34+/kg = 3.6–6.0 × 10⁸ cells total
# Multi-stage encounter timeline
Day −180 to −120: SCD diagnosis confirmation, VOC documentation, HSCT eligibility eval, fertility counseling, hematologic-malignancy REMS enrollment
Day −120: Apheresis HSC collection (outpatient, QTC) — CPT 38206 / 0540T
Day −120 to −7: ex vivo lentiviral transduction at bluebird facility (~3–6 months)
Day −7 to −3: Busulfan myeloablative conditioning — J0594 or NOC
Day 0: Autologous HSC infusion — HCPCS J3590 + CPT 38241
Day +14 to +28: Neutrophil engraftment (ANC ≥ 500 × 3 days)
Day +30 to +45: Platelet engraftment, discharge planning
Day +60 to +365: Outpatient follow-up; HbA-T87Q / HbA / Hb electrophoresis monitoring
Months 6, 12, 24, 60: Outcomes milestone reporting (bluebird Patient Services / payer OBA)
Year 1–15: Lifelong CBC w/diff hematologic-malignancy surveillance (BOXED warning)
# Billing claim line (HSC infusion encounter)
Drug: J3590 · 1 unit per patient-specific HSC product (NOC; per-treatment, not per cell)
Admin: CPT 38241 (Hematopoietic progenitor cell transplant; autologous)
Apheresis (prior encounter): CPT 38206 (HSC apheresis; autologous) or 0540T (category III for HSC therapy product, autologous transplantation)
Conditioning: J-code for high-dose busulfan (J0594) or NOC
# Course cost (manufacturer WAC + facility)
Lyfgenia product (WAC): ~$3,100,000 (one-time)
Apheresis + manufacturing handling: ~$50,000–$100,000
Busulfan conditioning + 30–45 d inpatient: ~$400,000–$900,000+
Total course estimate: ~$3.6M–$4.5M
Dose modifications
There is no dose-reduction pathway. Per FDA label, the minimum infused dose is 3 × 10⁶ CD34+ cells/kg. If the manufactured product fails to meet this minimum (due to low apheresis yield or low transduction efficiency), the infusion is held and a second apheresis collection is attempted. Repeat manufacturing adds another 3–6 months to the timeline. Patients undergoing repeat apheresis remain on standard SCD supportive care (transfusion, hydroxyurea) in the interim.
Fertility preservation
Busulfan myeloablation is gonadotoxic. All Lyfgenia candidates of reproductive age must receive fertility preservation counseling and access to sperm/oocyte/embryo banking before initiating busulfan. bluebird Patient Services coordinates fertility-preservation referrals. Document the fertility-preservation discussion and the patient's election in the chart and the PA packet.
NDC reference FDA NDC Directory verified May 2026
| NDC (10/11-digit) | Package | Use |
|---|---|---|
73554-100-01 / 73554-0100-01 |
Patient-specific cryopreserved bag of autologous lentivirus-transduced CD34+ HSCs; minimum 3 × 10⁶ CD34+ cells/kg dose; cell count and lot are patient-identified | Single one-time IV infusion; product is patient-specific and not interchangeable; do not return unused product to manufacturer (the patient's own cells) |
Patient-specific NDC pattern. Like CAR-T, Casgevy, Zolgensma, and other autologous one-off
therapies, Lyfgenia ships as a patient-specific, lot-traceable bag. The carton NDC reflects the product
family rather than a fixed activity. Document the patient-identified bag lot number, CD34+ cell count, vector
copy number (VCN), and total administered volume from the dose-build record before posting the claim. Submit
the carton-level 11-digit NDC with N4 qualifier in the appropriate UB-04 / 837I field. Verify the current
published NDC in the FDA NDC Directory; cell-therapy NDC assignments evolve as manufacturers update labeling.
Chain-of-custody & cold-chain constraint: The patient's HSCs are collected by apheresis
at the QTC, cryopreserved, shipped to a bluebird bio manufacturing facility, transduced with the BB305
lentiviral vector and expanded over ~3–6 months, then shipped back cryopreserved to the same QTC.
Manufacturing-related cancellations and out-of-specification products are rare but operationally significant;
engage bluebird Patient Services at the time of confirmed-eligibility (genetic confirmation +
vaso-occlusive-event documentation + HSCT eligibility evaluation + REMS enrollment) to lock the apheresis date
and reserve manufacturing capacity.
Phase 2
Code the claim
Multi-stage encounter — apheresis (38206/0540T), busulfan conditioning, HSC infusion (J3590 + CPT 38241), and ~30–45 day inpatient engraftment monitoring. QTC-only.
Multi-stage encounter codes CPT / HCPCS verified May 2026
Lyfgenia is not a single-encounter J-code event. Each of the five phases has its own billable codes. The patient-specific HSC product itself bills under J3590 (NOC) with CPT 38241 administration.
Phase 1 — Apheresis HSC collection (outpatient, ~6 months pre-infusion)
| Code | Description | When to use |
|---|---|---|
38206 |
Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous | Primary apheresis code for Lyfgenia. Multiple collections may be required to meet the manufacturing minimum (mobilization with plerixafor monotherapy; G-CSF is contraindicated in SCD due to VOC risk) |
38205 |
Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic | NOT used for Lyfgenia (autologous only) |
0540T |
Hematopoietic progenitor cell (HPC); HPC boost (or HPC harvest, autologous transplant) — category III | Some payers prefer the category III code for HSC-therapy-product apheresis specifically (distinct from generic autologous HSCT apheresis). Verify with payer and MAC. |
J2562 |
Injection, plerixafor, 1 mg | Mobilization agent for SCD apheresis (G-CSF is avoided due to VOC risk); bill per mg administered. SCD apheresis typically uses plerixafor monotherapy with red-cell exchange pre-conditioning. |
| Apheresis E/M and supportive care | Standard outpatient E/M (99202–99215) + IV fluids + pre-medication | Hydration is critical in SCD apheresis to prevent VOCs; exchange transfusion is often required pre-apheresis to target HbS < 30% per institutional protocol |
Phase 2 — Ex vivo lentiviral transduction (no billable services; bluebird internal)
The 3–6 month ex vivo lentiviral transduction with the BB305 vector, expansion, QC (vector copy number, transduction efficiency, sterility), and cryopreservation is performed at the bluebird bio manufacturing facility. There are no provider-side billable services during this window. The patient remains on standard SCD supportive care (hydroxyurea, transfusion, exchange transfusion as needed) coordinated by the QTC.
Phase 3 — Busulfan myeloablative conditioning (inpatient)
| Code | Description | When to use |
|---|---|---|
J0594 |
Injection, busulfan, 1 mg | Per-mg J-code for IV busulfan. High-dose myeloablative regimen is typically over 4 days; PK-adjusted (target AUC ~5000–6000 micromol·min/L per institutional HSCT protocol). Bill total mg administered per dose-build record. |
J3490 / J3590 |
Unclassified drug; unclassified biologics | Used if J0594 is not yet active or the payer requires NOC for the busulfan conditioning regimen (rare) |
96413 / 96415 / 96417 |
Chemotherapy administration, IV infusion; initial and additional hour | Yes — appropriate for busulfan. Busulfan is cytotoxic chemotherapy used as conditioning; the chemo admin family applies (unlike the Lyfgenia HSC infusion itself, which is not chemo) |
| Supportive care | Anti-emetics, antibiotic / antifungal / antiviral prophylaxis, seizure prophylaxis (busulfan), VOD/SOS surveillance | Bundled into inpatient HSCT supportive-care order set; bill individual J-codes per agent (e.g., ondansetron J2405, fosaprepitant J1453, defibrotide J3490 if VOD develops) |
Phase 4 — Autologous HSC infusion (the Lyfgenia product itself)
| Code | Description | When to use |
|---|---|---|
J3590 |
Unclassified biologics | Primary HCPCS for the Lyfgenia product as of 2026. Bill 1 unit per patient-specific HSC product. Submit invoice attachment + lot number + cell count + vector copy number to the payer. Some MACs prefer J3490 (unclassified drugs); some hospital-outpatient settings use C9399. Verify quarterly. |
C9399 |
Unclassified drug or biological for hospital outpatient prospective payment system (HOPPS) | Used for hospital outpatient transitional pass-through claim presentation; some MACs route Lyfgenia product claims through C9399 in the outpatient setting before a permanent J-code is published. |
38241 |
Hematopoietic progenitor cell transplantation; autologous | Primary administration CPT for Lyfgenia. Bill once per HSC infusion encounter. Includes the infusion itself; does NOT include the product, the conditioning, or the supportive care. |
38240 |
Hematopoietic progenitor cell transplantation; allogeneic | NOT used for Lyfgenia (autologous only) |
96365 |
Therapeutic IV infusion, initial 1 hour | NOT appropriate for the HSC product itself — HSC infusions are billed under 38241 (HSCT-specific code), not the generic therapeutic IV family. 96365 may apply to other concurrent therapeutic infusions during the inpatient stay. |
79101 |
Radiopharmaceutical therapy by intravenous administration | NOT appropriate. Lyfgenia is not radioactive. |
Phase 5 — Engraftment monitoring (~30–45 d inpatient, then outpatient through year 15+)
- Inpatient HSCT supportive care: bundled into the HSCT DRG; itemized for documentation only. Includes daily CBC, daily metabolic panel, daily LFTs, infectious-disease surveillance, transfusion support (RBC and platelets while autologous-transduced HSCs engraft), TPN if mucositis, antibiotic / antifungal / antiviral prophylaxis, GVHD surveillance (rare in autologous setting but documented), VOD/SOS surveillance.
- Outpatient follow-up: at months 1, 2, 3, 6, 9, 12, 18, 24 and longer. Standard E/M (99214–99215) + CBC with differential (85025) + hemoglobin electrophoresis (83020/83021) + reticulocyte count (85044) + ferritin (82728) + chemistry panel + as-indicated organ-function labs.
- Outcomes milestone reporting (months 6, 12, 24, 60): data submitted to bluebird Patient Services for outcomes-based contract milestone verification (no separate billable CPT; this is administrative documentation tied to the payer OBA).
- Hematologic malignancy long-term surveillance (BOXED warning — year 15 minimum): ongoing CBC with differential, peripheral blood smear, and (per clinical indication) bone marrow biopsy / cytogenetics / molecular evaluation. Enrollment in bluebird's long-term follow-up program is required for all Lyfgenia recipients.
HSC infusion is NOT chemotherapy admin. A common coding error: the busulfan conditioning is
chemo (96413 family), but the autologous HSC infusion itself (the Lyfgenia product) is billed under the
HSCT-specific CPT 38241, not under any chemo or generic therapeutic IV family. Keep these two separate on the
claim.
Modifiers CMS verified May 2026
JZ / JW — generally N/A for autologous patient-specific cell product
The Lyfgenia product is patient-specific, lot-identified, and built to deliver the patient's own lentivirus-transduced HSCs. There is no physical "vial waste" in the conventional J-code sense — the entire shipped product is intended for administration to that named patient. JZ may be reported on J3590 to attest "no discarded amount," but practice varies by MAC and the NOC / per-product unit definition makes JZ/JW reporting largely moot. Confirm with your MAC.
Modifier 25 — same-day E/M
Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the HSC infusion or apheresis collection (consent, extended family counseling, fertility-preservation discussion, baseline HSCT eligibility review, REMS enrollment).
340B modifiers (JG, TB)
Lyfgenia is dispensed through the bluebird specialty distribution channel rather than via 340B in most cases. A small number of DSH/CAH hospitals with established autologous HSCT programs may administer 340B-acquired busulfan and supportive-care drugs (the Lyfgenia product itself is rarely 340B). Confirm with your 340B compliance team. Outcomes-based contracts can complicate 340B reporting because the manufacturer rebate flow interacts with 340B pricing assumptions.
Contract-specific modifiers
Some commercial payers add a contract-specific modifier or claim attachment requirement to flag claims under an outcomes-based agreement (so the claim can be linked to the manufacturer's milestone-tracking dataset). Follow the payer's outcomes-based contract operational guide; bluebird Patient Services coordinates this end-to-end. The CMS CGT Access Model has standardized identifiers for sickle cell gene therapy claims for participating state Medicaid programs.
ICD-10-CM by indication FY2026 verified May 2026
Lyfgenia is indicated for SCD (D57.x) only. D56.x β-thalassemia codes are NOT applicable — Lyfgenia has no TDT indication. Use indication-specific D57.x codes and document a history of vaso-occlusive events.
| Indication | ICD-10 code | Notes |
|---|---|---|
| Hb-SS disease with crisis, with vaso-occlusive crisis (VOC) | D57.00 / D57.01 | Most common SCD genotype for Lyfgenia eligibility; document history of vaso-occlusive events on optimized supportive care including hydroxyurea |
| Sickle-cell / Hb-C disease with crisis (HbSC) | D57.20x / D57.21x | Eligible per label if history of vaso-occlusive events documented |
| Sickle cell / β-thalassemia (HbS-β-thal) | D57.40x / D57.41x | Eligible per label; document history of vaso-occlusive events |
| Sickle-cell trait | D57.3 | NOT eligible (carrier state, not SCD) |
| β-thalassemia major (Cooley's anemia, TDT) | D56.1 | NOT eligible for Lyfgenia; Lyfgenia has no TDT indication. Refer to Casgevy. |
| HbE-β-thalassemia | D56.5 | NOT eligible for Lyfgenia; refer to Casgevy. |
| Long-term use of iron chelator | Z79.899 | Document chelator history (deferasirox, deferoxamine, deferiprone) for transfusion-burdened SCD patients |
| History of stem cell transplant | Z94.81 | Apply post-infusion for the patient's long-term record |
| Encounter for prophylactic measures (mobilization, conditioning) | Z29.8 | Use for the apheresis mobilization and busulfan conditioning encounters as appropriate per payer mapping |
Genetic confirmation is the gating criterion. Lyfgenia is indicated only for patients with
genetically confirmed SCD. Documentation must include the hemoglobinopathy genetic / hemoglobin-electrophoresis
report (genotype HbSS / HbSC / HbS-β-thal) plus VOC history. Sickle-cell trait (D57.3) is
not eligible. β-thalassemia (D56.1, D56.5) is not a Lyfgenia indication;
refer those patients to Casgevy. Document a history of vaso-occlusive events on optimized supportive care
including hydroxyurea.
Site of care & place of service Verified May 2026
Lyfgenia is administered exclusively at bluebird-credentialed Qualified Treatment Centers (QTCs): FACT-accredited HSCT-eligible facilities with established autologous HSCT programs, busulfan dose-banding experience, apheresis capability, post-transplant supportive-care infrastructure, and hematologic-malignancy long-term follow-up capability. Office-based (POS 11) and ambulatory infusion center (POS 49) administration are categorically not appropriate. The dominant billing setting is hospital inpatient (POS 21) for the busulfan + HSC infusion + ~30–45 day engraftment admission, with hospital outpatient (POS 22) for the prior apheresis collection and the post-discharge follow-up.
| Setting | POS | Claim form | Eligible? |
|---|---|---|---|
| QTC hospital inpatient (busulfan + HSC infusion + engraftment admission) | 21 | UB-04 / 837I | Yes — dominant setting; HSCT DRG bundling with high-cost outlier or NTAP for the Lyfgenia product |
| QTC hospital outpatient (apheresis collection ~6 mo pre-infusion) | 22 | UB-04 / 837I | Yes — primary apheresis setting |
| QTC hospital outpatient (post-discharge follow-up, mo 1–24) | 22 | UB-04 / 837I | Yes — primary follow-up setting; standard outpatient E/M + labs |
| Non-QTC academic medical center | 21/22 | UB-04 | No — QTC restriction; patient must be referred to a credentialed center |
| Community hospital / non-HSCT center | 21/22 | UB-04 | No — HSCT-eligible facility required |
| Physician office | 11 | n/a | No — not appropriate for myeloablative HSCT |
| Ambulatory infusion suite (AIC) | 49 | n/a | No — QTC restriction |
| Patient home | 12 | n/a | No |
QTC certification process: bluebird credentials QTCs on FACT accreditation, autologous HSCT
program track record, busulfan PK-adjusted dosing experience, apheresis volume (SCD apheresis is operationally
distinct from oncology apheresis due to VOC risk), cryopreservation chain-of-custody, post-transplant
infectious-disease infrastructure, fertility-preservation referral network, hematologic-malignancy long-term
follow-up capability, and outcomes-data reporting capability. Most QTCs are large academic medical centers
with established BMT programs (and many are also Casgevy ATCs). The list is maintained at lyfgenia.com/hcp.
Administering at a non-QTC is the #2 cause of Lyfgenia claim denial.
Long inpatient stay drives total course cost. The ~30–45 day inpatient stay for
busulfan + HSC infusion + engraftment monitoring is bundled into the HSCT DRG (DRG 014-017 autologous BMT
family). The Lyfgenia product itself (J3590) typically triggers a high-dollar outlier payment or NTAP because
the WAC vastly exceeds the standard DRG payment. Confirm the hospital's contracted reimbursement with the
payer before the inpatient admission; uncontrolled DRG bundling without outlier payment is not financially
viable.
Claim form field mapping bluebird Patient Services 2026
Lyfgenia claims are typically submitted on UB-04 (837I) by the QTC. Multiple distinct encounters across the multi-stage course; each has its own claim.
| Information | UB-04 field | Notes |
|---|---|---|
| NPI (facility / rendering) | FL 56 / FL 76–79 | QTC and attending hematology / BMT physician |
| HCPCS J3590 + revenue code 0636 | FL 42 (rev code) + FL 44 (HCPCS) | Revenue code 0636 = "Drugs requiring detailed coding" for the patient-specific HSC product; some payers map to 0815 (allogeneic stem cell acquisition) or a payer-specific cell-therapy revenue code |
| Units (per product) | FL 46 | 1 unit per patient-specific HSC product (NOC; do NOT bill per cell or per mL) |
| CPT 38241 + revenue code 0815 | FL 42 (rev code) + FL 44 (CPT) | Revenue code 0815 = "Autologous stem cell acquisition"; 38241 = HSCT autologous |
| CPT 38206 + revenue code 0815 (prior encounter) | FL 42 + FL 44 | Apheresis encounter ~6 months earlier; submit as a separate UB-04 at the time of collection |
| J0594 (busulfan) + revenue code 0636 | FL 42 + FL 44 | Bill total mg per dose-build over the 4-day conditioning regimen |
| NDC qualifier + 11-digit NDC + UoM + qty | FL 43 / shaded line | N4 + product NDC + UN (unit) + 1; include patient-specific bag lot number and vector copy number in claim notes per payer |
| ICD-10 | FL 67 + 67A–Q | D57.x for SCD primary (D56.x NOT applicable); Z29.8, Z79.899, Z94.81 as documented; document VOC history |
| PA number | FL 63 | Required by all payers; document genetic confirmation, history of vaso-occlusive events, prior therapy history (hydroxyurea, exchange transfusion), HSCT eligibility, QTC certification, fertility-preservation plan, hematologic-malignancy REMS enrollment |
| Outcomes-based contract identifier | FL 80 / attachment | If applicable per payer; CMS CGT Access Model identifier for participating state Medicaid; flag the claim for milestone tracking (3–5 year horizon) |
| DRG (inpatient) | FL 71 | HSCT DRG family (DRG 014-017 autologous BMT) per current grouper; outlier payment or NTAP applies for the Lyfgenia product cost |
| Modifier (if any) | FL 44 modifier line | JZ optional per MAC; contract-specific modifier per outcomes agreement; 340B JG/TB if applicable (rare for the Lyfgenia product itself) |
Document the workflow timeline. Beyond the claim, the patient record must show: genetic
confirmation report, history of vaso-occlusive events with dates / severity / hospitalizations, hydroxyurea
trial and outcome, HSCT eligibility evaluation, fertility preservation discussion and election, QTC
certification, apheresis date and yield, manufacturing dates, vector copy number (VCN) from bluebird release
record, busulfan dose-build and PK targets, HSC infusion date and cell count, engraftment dates (ANC ≥ 500,
platelet ≥ 20K and ≥ 50K), discharge summary, hematologic-malignancy REMS enrollment
confirmation, and the long-term outcomes-tracking plan. This documentation supports the PA, the
HSCT DRG, the outlier/NTAP, the manufacturer's outcomes-based contract milestone verification at 3–5
years, and the year-15 boxed-warning surveillance commitment.
Phase 3
Get paid
SCD genetic confirmation + history of vaso-occlusive events + QTC certification + HSCT eligibility + hematologic-malignancy REMS enrollment are the gating PA criteria. CMS CGT Access Model is the dominant Medicaid framework.
Payer policy snapshot Reviewed May 2026
Universal PA. Genetic confirmation, history of vaso-occlusive events, prior hydroxyurea trial, QTC certification, HSCT eligibility, fertility-preservation plan, and hematologic-malignancy REMS enrollment are the universal documentation requirements. The boxed warning is the operationally significant differentiator vs Casgevy in many policies.
| Payer | PA? | Key documentation requirements | Outcomes-based contract? |
|---|---|---|---|
| UnitedHealthcare Gene Therapy Medical Policy |
Yes | Age ≥ 12 yr; genetic confirmation HbSS/HbSC/HbS-β-thal; history of vaso-occlusive events on optimized supportive care including hydroxyurea; QTC certification; HSCT eligibility evaluation; fertility-preservation counseling; baseline organ function; boxed-warning consent + hematologic-malignancy REMS enrollment; some plans prefer Casgevy because of cleaner safety label and require Lyfgenia-specific rationale | Yes (Optum gene therapy benefit) |
| Aetna CPB Lovotibeglogene Autotemcel |
Yes | FDA-label-aligned; SCD with history of vaso-occlusive events; QTC restriction; specialty review; boxed-warning monitoring plan documented | Yes (case-by-case) |
| BCBS plans Vary by plan |
Yes | Generally aligned with FDA label and ASH / ASH-ASTCT guidelines for SCD; some Blues plans participate in CMS CGT Access Model; some have specific gene-therapy benefit pools; many Blues require explicit rationale for Lyfgenia over Casgevy given boxed warning | Common at large plans |
| Cigna / Evernorth | Yes | FDA-label-aligned; QTC; comprehensive documentation packet including hematologic-malignancy long-term follow-up plan; Accredo specialty channel | Yes (Accredo specialty channel) |
| State Medicaid (CGT Access Model participating) | Yes | CMS Cell and Gene Therapy Access Model (launched Jan 2025); standardized outcomes metrics and pricing for SCD gene therapies (Casgevy and Lyfgenia) for participating state Medicaid programs | Yes (CMS-administered) |
| State Medicaid (non-participating) | Yes | State-specific; supplemental rebate agreements (SRA) and outcomes-based agreements common; alignment with FDA label and boxed-warning REMS | Common (state-specific) |
CMS Cell and Gene Therapy (CGT) Access Model
Launched January 2025, the CMS CGT Access Model is a multi-state framework in which CMS negotiates outcomes-based agreements with manufacturers of sickle cell gene therapies (Casgevy and Lyfgenia) on behalf of participating state Medicaid programs. The model standardizes outcomes metrics (severe VOC events, transfusion utilization, hospitalization), pricing structure, and milestone-tracking timelines. State Medicaid programs that opt in delegate negotiation to CMS in exchange for risk-sharing on outcomes. As of 2026 the participation roster includes >20 state Medicaid agencies and is expanding. The provider's operational impact: a standardized outcomes-data reporting workflow coordinated through bluebird Patient Services, and a CGT Access Model identifier on the inpatient claim.
Outcomes-based contracts — how they work for billers
bluebird bio offers outcomes-based agreements (OBAs) with most major commercial payers and the CMS CGT Access Model for participating state Medicaid. Typical structure: full WAC (~$3.1M) is paid at administration; if specified clinical milestones (e.g., absence of severe VOCs) are not met over a 3–5 year horizon, a percentage of WAC is refunded by bluebird to the payer. The provider's role: document the clinical outcome data (severe VOC events, transfusion events, HbA-T87Q and HbA levels, hospitalizations, hematologic-malignancy surveillance results) at standardized intervals (months 6, 12, 24, 60, then annually through year 15). bluebird Patient Services coordinates this longitudinally. The rebate/refund flow is payer-side and does not affect the provider's payment at administration.
Step therapy & prior SCD therapy
Most payers require documented adequate trial of hydroxyurea (typically ≥6–12 months at maximum tolerated dose) with persistent vaso-occlusive events before authorizing Lyfgenia. Crizanlizumab (Adakveo) and voxelotor (Oxbryta, voluntarily withdrawn 2024) trials may be requested by some payers but are not universally required after the Oxbryta withdrawal. Document the prior-therapy history, response, and clinical rationale for selecting Lyfgenia (vs Casgevy) in the PA packet — this is increasingly important given the Lyfgenia boxed warning and some plans' preference for Casgevy.
Medicare / Medicaid reimbursement CMS Q2 2026 (NOC / invoice; CGT Model active)
Most Lyfgenia patients are adolescent / young adult Medicaid (SCD demographics) or commercial. For inpatient HSCT administration, the Lyfgenia product is packaged into the HSCT DRG with high-dollar outlier payment or NTAP; the CMS CGT Access Model standardizes Medicaid pricing for participating states.
Lyfgenia payment framework
One-time lentivirus-transduced HSC product · product payment via NOC / invoice plus HSCT DRG outlier; outcomes-based contracts and CMS CGT Model dominant
Product WAC
~$3.1M
manufacturer WAC, one-time
Total course (incl. facility)
~$3.6M–$4.5M
drug + apheresis + conditioning + 30–45 d admission
CMS CGT Model states
>20
participating state Medicaid (2026)
ASP does not apply in the conventional sense. Lyfgenia is a one-time patient-specific
autologous cell product with no quarterly volume-weighted utilization. CMS prices it via invoice / NOC
rather than via the quarterly ASP file. Verify the current quarter's MEDICARE_ASP entry (J3590 is an NOC
code and will not have a Lyfgenia-specific line). Most commercial plans and the CMS CGT Access Model use the
manufacturer WAC or a CGT-Model-negotiated price as the payment basis.
HSCT DRG packaging + outlier: When Lyfgenia is administered inpatient (the dominant setting),
the patient is grouped into the autologous BMT DRG family (DRG 014-017 per current MS-DRG grouper). Lyfgenia's
WAC vastly exceeds the standard DRG payment, so the inpatient claim almost always triggers a high-dollar
outlier payment. For Medicare, the New Technology Add-On Payment (NTAP) pathway may apply depending on
Lyfgenia's NTAP status for the current fiscal year; verify CMS IPPS final rule for the current FY. State
Medicaid programs have negotiated SRAs or participate in the CMS CGT Access Model for standardized pricing.
Inpatient (Medicare / Medicaid)
Lyfgenia is administered inpatient (busulfan conditioning + HSC infusion + 30–45 d engraftment monitoring). The HSC product cost is bundled into the assigned HSCT DRG (014-017) with outlier payment or NTAP. Confirm the hospital's contracted reimbursement with the payer before the inpatient admission; bundling without outlier is not viable. The CMS CGT Access Model provides a standardized Medicaid pricing framework for participating states.
Outpatient (Medicare / Medicaid)
The apheresis collection (~6 months pre-infusion) is the dominant outpatient encounter and is billed at the QTC under CPT 38206 (or 0540T) with revenue code 0815 (autologous stem cell acquisition). Outpatient billing of the Lyfgenia product itself is uncommon because of the busulfan and ~30–45 day engraftment monitoring requirement; the HOPPS Addendum B may include C9399 transitional pass-through guidance for the product in edge cases.
Coverage
No NCD specific to Lyfgenia or to ex vivo gene-modified HSC therapies generally. Coverage falls under MAC LCDs and payer-specific medical / pharmacy benefit policies. All MACs and major commercial payers cover Lyfgenia for FDA-approved on-label indications with documented genetic confirmation, history of vaso-occlusive events, prior hydroxyurea trial, QTC certification, HSCT eligibility, and hematologic-malignancy REMS enrollment.
Code history
- J3590 — "Unclassified biologics"; used as primary HCPCS for the Lyfgenia product pending a permanent product-specific J-code. Verify the current CMS HCPCS quarterly file for any transition to a permanent code.
- C9399 — HOPPS transitional pass-through; used in hospital outpatient setting where applicable. New cell and gene therapies typically receive transitional C-codes before permanent J-codes.
- J3490 — "Unclassified drug"; some payers route Lyfgenia claims through J3490 instead of J3590; either NOC code is acceptable per payer guidance.
- Future permanent J-code: likely to be assigned in a future CMS HCPCS quarterly update; monitor the quarterly file release.
Patient assistance — bluebird Patient Services bluebird verified May 2026
- bluebird Patient Services (Lyfgenia): 1-833-999-6760 / lyfgenia.com/hcp — benefits investigation, prior authorization assistance, QTC referral, apheresis logistics, manufacturing chain-of-custody, travel and lodging coordination for the ~6-week QTC stay, fertility-preservation counseling pre-busulfan, outcomes-based contract administration, hematologic-malignancy long-term follow-up REMS enrollment, longitudinal post-infusion follow-up through year 15+
- bluebird Patient Assistance Program (PAP): free product for uninsured / underinsured patients meeting income requirements; Lyfgenia access pathway is highly individualized given the WAC scale and the HSCT facility cost stack
- Sickle Cell Disease Association of America (SCDAA): sicklecelldisease.org — SCD advocacy, peer/family support, treatment-center directory, emergency financial assistance for travel and lodging while at the QTC, education resources
- Foundations: PAN Foundation (rare/genetic disease funds where applicable), HealthWell Foundation, Patient Advocate Foundation — primarily supplemental for non-drug costs (travel, lodging, post-transplant care, hematologic-malignancy surveillance labs); verify open SCD / rare-disease funds quarterly
- BMT InfoNet (bmtinfonet.org): autologous HSCT family support, transplant-center directory, post-transplant resource library
- Travel & lodging: bluebird Patient Services coordinates with Healthcare Hospitality Network, Ronald McDonald House (for adolescent patients), Hope Lodge, and QTC-affiliated patient housing for the ~6-week inpatient + outpatient QTC stay
Need to model what a specific patient's family will actually pay across the multi-stage course (apheresis,
manufacturing, conditioning, HSC infusion, 30–45 day admission, post-discharge follow-up) after copay
assistance, deductible, coinsurance, and OOP max?
Run a CareCost Estimate — J3590 pre-loaded with the multi-stage Lyfgenia
workflow.
Phase 4
Fix problems
Missing SCD genetic confirmation, administration at non-QTC, inadequate VOC documentation, pediatric < 12 attempted, missing HSCT eligibility, missing hematologic-malignancy REMS enrollment, and TDT-attempted (Lyfgenia has no TDT indication) are the top denial drivers.
Safety & FDA-label monitoring FDA boxed warning + W&P
BOXED WARNING — hematologic malignancy. Lyfgenia carries an FDA boxed warning for
hematologic malignancy. Cases of myeloid malignancy (acute myeloid leukemia, myelodysplastic syndrome) have
been reported in patients treated with Lyfgenia. The hypothesized mechanism combines (1) BB305 lentiviral
vector semi-random integration into the host HSC genome (insertional mutagenesis risk), (2) busulfan
myeloablation genotoxicity, and (3) the baseline elevated malignancy risk in sickle cell disease. Per
the FDA label, monitor patients with CBC with differential at least every 6 months and
integration site analysis at months 6, 12, and as warranted; bone marrow evaluation if cytopenias or
dysplastic features. A 15-year long-term follow-up post-marketing study commitment captures
hematologic-malignancy surveillance and insertional-mutagenesis tracking; all Lyfgenia recipients must be
enrolled in bluebird's long-term follow-up program. This is the operationally significant safety differentiator
vs Casgevy.
FDA-label warnings & precautions
- Hematologic malignancy (BOXED): see above. Per label, monitor CBC with differential at least every 6 months and integration site analysis at months 6, 12, and as warranted; peripheral smear, bone marrow biopsy / cytogenetics / molecular evaluation as clinically indicated. The 15-year long-term follow-up is a post-marketing study commitment for hematologic-malignancy surveillance and insertional-mutagenesis tracking. Enroll patients in bluebird's LTFU program at the PA stage.
- Prolonged cytopenias: profound neutropenia and thrombocytopenia after busulfan conditioning are expected; delayed platelet engraftment has been observed in Lyfgenia clinical trials; monitor daily CBC during the inpatient stay; manage with G-CSF (filgrastim, pegfilgrastim — carefully dosed given SCD baseline VOC risk) and platelet transfusions per HSCT protocol.
- Infection: bacterial, fungal, and viral infection risk during the cytopenic window; antibiotic / antifungal / antiviral prophylaxis per institutional HSCT protocol.
- Hepatic veno-occlusive disease / sinusoidal obstruction syndrome (VOD/SOS): busulfan conditioning carries a small but serious VOD/SOS risk; surveillance includes daily weight, daily LFTs, abdominal exam, doppler imaging if suspected; defibrotide is the standard rescue therapy.
- Engraftment failure: rare with autologous transduced HSC; if neutrophil engraftment is not achieved by day +28 or platelet engraftment by day +45, consider product re-dosing (with available cryopreserved aliquot) or rescue allogeneic HSCT per institutional protocol.
- GVHD: graft-vs-host disease is rare in autologous HSCT (donor and recipient are the same patient) but documented in label; clinical vigilance during engraftment.
- Infertility: busulfan myeloablation is gonadotoxic; fertility preservation must be discussed and offered pre-treatment.
- Vaccinations: live vaccines are deferred during the early post-transplant immune reconstitution window per ASH-ASTCT post-HSCT immunization guidelines; coordinate with infectious disease.
Outcomes-based milestone tracking
Beyond the FDA-label safety monitoring, the manufacturer's outcomes-based contract and the CMS CGT Access Model require documentation of clinical milestones at months 6, 12, 24, and 60 post-infusion: absence of severe vaso-occlusive crises, hospitalization rate, transfusion utilization, HbA-T87Q and HbA levels. Standardized outcomes-data instruments are coordinated through bluebird Patient Services. The long-term follow-up registry continues through year 15 minimum for hematologic-malignancy surveillance per the boxed warning.
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| SCD genetic confirmation missing | PA submitted without hemoglobinopathy genotyping report or hemoglobin electrophoresis confirming HbSS / HbSC / HbS-β-thal | Submit genetic / electrophoresis report confirming the specific genotype. Sickle-cell trait (D57.3) is not eligible. This is the #1 cause of Lyfgenia denial. |
| Administration at non-QTC facility | Patient routed to a facility not on bluebird's Qualified Treatment Center (QTC) list | Re-route the patient to a credentialed QTC; bluebird Patient Services maintains the directory at lyfgenia.com/hcp. Non-QTC facilities cannot order or administer Lyfgenia. #2 cause of denial. |
| Vaso-occlusive event documentation gaps | PA packet does not document a history of vaso-occlusive events on optimized supportive care including hydroxyurea | Submit detailed VOC log: dates, severity, hospitalizations, ED visits, exchange transfusions, opioid utilization. Document hydroxyurea trial (dose, duration, response, HbF response). #3 cause of denial. |
| Patient < 12 years | Pediatric patient attempted despite FDA label cutoff of ≥12 yr | Lyfgenia is not FDA-approved for patients < 12 yr. Maintain on standard SCD supportive care until eligibility age. #4 cause of denial. |
| HSCT eligibility evaluation incomplete | PA packet missing transplant-eligibility workup (cardiac, pulmonary, hepatic, renal function; infectious-disease screen; PFTs; ECHO; psychosocial) | Complete the standard pre-HSCT eligibility evaluation per QTC protocol; document all organ-function and psychosocial criteria. #5 cause of denial. |
| Hematologic-malignancy REMS enrollment missing | PA packet does not document patient enrollment in bluebird's long-term follow-up program for hematologic-malignancy surveillance per boxed warning | Enroll patient at lyfgenia.com/hcp / bluebird Patient Services; document REMS enrollment confirmation in PA packet. #6 cause of denial — specific to Lyfgenia (Casgevy has no boxed warning). |
| β-thalassemia (TDT) attempted on Lyfgenia | PA submitted for transfusion-dependent β-thalassemia patient under Lyfgenia — Lyfgenia has no TDT indication | Refer patient to Casgevy (which covers both SCD and TDT). Resubmit PA accordingly. #7 cause of Lyfgenia denial. |
| Hydroxyurea trial not documented | PA packet does not document an adequate hydroxyurea trial (≥6–12 months at maximum tolerated dose) with persistent vaso-occlusive events | Document hydroxyurea dose, duration, response (HbF, ANC, MCV), and the persistent-VOC rationale for escalating to Lyfgenia. |
| Fertility-preservation plan not documented | PA packet missing fertility-preservation counseling for a patient of reproductive age before busulfan myeloablation | Document fertility-preservation discussion and patient election (sperm banking, oocyte / embryo cryopreservation, or declined with rationale). bluebird Patient Services coordinates referrals. |
| Lyfgenia-vs-Casgevy rationale missing | Payer requires explicit clinical rationale for choosing Lyfgenia (boxed warning) over Casgevy (no boxed warning) | Document clinical-team rationale for Lyfgenia selection (mechanism preference, institutional familiarity, prior bluebird relationships, patient/family preference after informed consent). Some payer policies require this explicit justification. |
| Wrong HCPCS (J9999, A9999, etc.) | Claim submitted under an inappropriate unclassified code | Resubmit under J3590 (unclassified biologics) or C9399 (HOPPS transitional pass-through) per payer guidance. J3490 may also be acceptable. Submit invoice attachment + patient-specific lot number + cell count + vector copy number. |
| Wrong admin CPT (96365 therapeutic IV instead of 38241 HSCT) | Coder applied generic IV admin family instead of HSCT-specific admin code | Resubmit with CPT 38241 (autologous HSCT) for the Lyfgenia product infusion. 96365 is not appropriate for HSC products. |
| Outcomes-based contract flag missing | Inpatient claim not linked to the OBA or CMS CGT Access Model milestone-tracking dataset | Apply the payer's outcomes-based contract identifier or the CMS CGT Access Model identifier per the contract operational guide; coordinate with bluebird Patient Services. Without the OBA flag, the manufacturer rebate / CGT Model rebate flow may break. |
Frequently asked questions
Is Lyfgenia a one-time treatment?
Yes. Lyfgenia is administered as a single one-time IV infusion of autologous lentivirus-modified CD34+ HSCs after busulfan myeloablative conditioning. There is no repeat or maintenance dose. The transduced HSCs engraft in the bone marrow and produce HbA-T87Q-expressing red cells for life. The full course is a multi-stage encounter spanning apheresis collection, ex vivo lentiviral transduction, busulfan conditioning, HSC infusion, and ~30–45 days of inpatient engraftment monitoring — followed by lifelong hematologic-malignancy surveillance per the boxed warning.
What is the HCPCS code for Lyfgenia?
As of 2026, Lyfgenia has no permanent product-specific J-code. Most claims are billed under
J3590 (unclassified biologics) or C9399 (HOPPS transitional pass-through) with
invoice-based pricing. Some payers accept J3490 (unclassified drugs). The autologous HSC
infusion is billed under CPT 38241 (HSCT autologous), and apheresis collection under
38206 or 0540T. Verify with your MAC and the current CMS HCPCS quarterly file
because cell and gene therapy coding evolves rapidly.
Why does Lyfgenia have a boxed warning?
Cases of myeloid malignancy (AML, MDS) have been reported in patients treated with Lyfgenia. The hypothesized mechanism combines (1) BB305 lentiviral vector semi-random integration into the host HSC genome (insertional mutagenesis risk), (2) busulfan genotoxicity, and (3) the baseline elevated malignancy risk in SCD. The label requires lifelong hematologic monitoring through year 15 minimum, and all recipients must enroll in bluebird's long-term follow-up REMS program. This is the operationally significant differentiator vs Casgevy (which has no boxed warning) at PA and in informed consent.
What is the #1 cause of Lyfgenia denial?
Missing genetic confirmation of SCD. The Lyfgenia label requires documented genetic confirmation of the hemoglobinopathy (HbSS / HbSC / HbS-β-thal) plus a history of vaso-occlusive events on optimized supportive care. PA submissions without the genotyping report, hemoglobin electrophoresis, or detailed VOC history are denied at intake. The Lyfgenia-specific #6 denial driver is failure to enroll in the hematologic-malignancy long-term follow-up REMS program required by the boxed warning.
Lyfgenia vs Casgevy — which to choose?
Both are autologous ex vivo modified HSC therapies for sickle cell disease, approved on the same day (Dec 8, 2023). Lyfgenia uses lentiviral transduction (BB305 vector) adding a modified β-globin transgene (bA-T87Q) and has a boxed warning for hematologic malignancy. Casgevy uses CRISPR/Cas9 editing of the BCL11A enhancer (restores HbF) and has no boxed warning. Both share the same multi-stage HSCT workflow, busulfan myeloablation, ~30–45 day inpatient stay, and large-dollar list prices ($3.1M Lyfgenia vs $2.2M Casgevy). Lyfgenia is SCD-only; Casgevy covers SCD and TDT. Most payers cover both; some plans prefer Casgevy because of the cleaner safety label. A patient can only receive one course of one product per lifetime.
How does Lyfgenia differ from AAV gene therapies like Zolgensma?
Mechanism and billing pathway are completely different. AAV gene therapies (Zolgensma, Hemgenix, Roctavian) deliver a transgene in vivo via an AAV vector; billing is a single infusion encounter under one J-code + 96365 admin. Lyfgenia is ex vivo gene addition via a lentiviral vector: HSCs collected by apheresis, shipped to a manufacturing facility, transduced over ~3–6 months, then reinfused after busulfan myeloablation. Billing is a multi-stage encounter (apheresis 38206 + busulfan J0594 + HSC infusion J3590 + CPT 38241 + ~30–45 d inpatient).
Why is busulfan myeloablation required?
Lyfgenia is an autologous HSC product. For the transduced HSCs to engraft in the bone marrow and produce HbA-T87Q-expressing red cells for life, the patient's existing sickle-cell hematopoietic compartment must first be cleared. High-dose busulfan myeloablative conditioning (typically 4 days, PK-adjusted) achieves this. Myeloablation is more intense than CAR-T's lymphodepletive conditioning, which is why the Lyfgenia inpatient stay is 30–45 days while CAR-T is typically 7–14 days. Busulfan carries risks of VOD/SOS, prolonged cytopenias, infection, infertility, and genotoxicity that compounds with the lentiviral vector insertional risk (part of the rationale for the hematologic-malignancy boxed warning).
What is a Qualified Treatment Center (QTC)?
bluebird credentials a network of QTCs that are the only sites permitted to administer Lyfgenia. QTCs are FACT-accredited HSCT-eligible facilities with established autologous HSCT programs, busulfan dose-banding experience, apheresis capability, cryopreservation infrastructure, post-transplant supportive-care capacity, and hematologic-malignancy long-term follow-up capability. The list is maintained at lyfgenia.com/hcp. Non-QTC facilities cannot order Lyfgenia. This is the #2 cause of Lyfgenia claim denials. Many QTCs are also Casgevy ATCs — the credentialing requirements overlap significantly.
Can a patient receive Lyfgenia for transfusion-dependent β-thalassemia?
No. Lyfgenia is NOT FDA-approved for TDT. Use Casgevy for the TDT indication. Submitting a PA for Lyfgenia with a primary D56.x diagnosis will be denied on the indication criterion. (Note: bluebird's prior product Zynteglo (betibeglogene autotemcel) was the TDT-indication lentiviral product, but it has been withdrawn from the US market in recent years; verify current availability if a TDT patient asks about a bluebird/lentiviral option.)
How long is the apheresis-to-infusion timeline?
Typically 3–6 months for ex vivo lentiviral transduction manufacturing alone, plus pre-apheresis evaluation, HSCT eligibility workup, and REMS enrollment (~1–2 months), and pre-infusion conditioning admission (~1 week). Total apheresis-to-infusion timeline is typically 5–9 months. Repeat apheresis (if first manufacturing run fails to meet the 3 × 10⁶ CD34+/kg minimum) adds another 3–6 months. Patients remain on standard SCD supportive care (hydroxyurea, exchange transfusion as needed) throughout.
What is the CMS Cell and Gene Therapy (CGT) Access Model?
Launched January 2025, the CMS CGT Access Model is a multi-state framework in which CMS negotiates outcomes-based agreements with manufacturers of sickle cell gene therapies (Casgevy and Lyfgenia) on behalf of participating state Medicaid programs. The model standardizes outcomes metrics, pricing, and milestone tracking. As of 2026 the participation roster includes >20 state Medicaid agencies and is expanding. Provider impact: a standardized outcomes-data reporting workflow coordinated through bluebird Patient Services, and a CGT Access Model identifier on the inpatient claim for participating states.
What about fertility preservation?
Busulfan myeloablation is gonadotoxic. All Lyfgenia candidates of reproductive age must receive fertility-preservation counseling and access to sperm, oocyte, or embryo banking before initiating busulfan. bluebird Patient Services coordinates fertility-preservation referrals. Document the discussion and the patient's election (or declined-with-rationale) in the chart and the PA packet.
Cost: how does $3.6M–$4.5M get paid for?
Through payer contracts, not patient out-of-pocket. Most patients are Medicaid (SCD demographics skew young and Medicaid-insured) or commercial. State Medicaid uses SRAs or the CMS CGT Access Model. Commercial payers use a combination of standard medical benefit + stop-loss reinsurance + outcomes-based contracts + benefit-pool carve-outs. Patient family OOP exposure is typically capped at the plan's OOP maximum, not the WAC. bluebird Patient Services and copay-assistance foundations help bridge any residual exposure.
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- DailyMed — LYFGENIA prescribing information (BLA 125788, setid 0d1b475e-5781-2bd1-e063-6294a90a7311; current label rev. Apr 7, 2026)
- DailyMed — LYFGENIA (lovotibeglogene autotemcel)
- bluebird bio — Lyfgenia professional / Patient Services site
- FDA press release — First gene therapies for sickle cell disease (Dec 8, 2023)
- CMS — Medicare Part B Drug ASP Pricing File
- CMS Innovation Center — Cell and Gene Therapy Access Model
- CMS — MS-DRG classifications (DRG 014-017 autologous BMT)
- Kanter et al., NEJM 2022 — Biologic and clinical efficacy of LentiGlobin for sickle cell disease (HGB-206 Group C)
- NEJM 2024 — Lovotibeglogene autotemcel for sickle cell disease (phase 3 confirmatory)
- Sickle Cell Disease Association of America (SCDAA)
- American Society of Hematology — SCD practice guidelines
- FACT — Foundation for the Accreditation of Cellular Therapy
- UnitedHealthcare — Lyfgenia Medical Drug Policy
- Aetna CPB — Lovotibeglogene Autotemcel
- FDA National Drug Code Directory
- CMS — JW/JZ modifier policy (CR 12056, eff. July 2023)
About this page
We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| Medicare ASP / OPPS status indicator | Quarterly | Auto-bound to CareCost ASP layer; OPPS Addendum B reviewed each calendar quarter. J3590 is NOC; product priced via invoice / NOC and the CMS CGT Access Model. |
| Payer policies (UHC, Aetna, BCBS, Cigna, state Medicaid, CMS CGT Model) | Semi-annual | Manual review against published payer policy documents; outcomes-based contract terms reviewed annually with bluebird Patient Services. |
| HCPCS / CPT / modifier rules | Annual | Reviewed against CMS HCPCS quarterly files and AMA CPT releases; monitor for transition from J3590 NOC to a permanent product-specific J-code. |
| NDC, dosing, FDA label, boxed warning, monitoring schedule | Event-driven | Tied to manufacturer document version + FDA label revision date; boxed-warning REMS workflow changes propagate immediately. |
Reviewer
Pending SME review. This page is staff-authored from primary sources (FDA, CMS, bluebird bio,
ASH, FACT, pivotal trial publications — all linked above). Editorial review in progress. Until that
review is complete, treat this as a draft reference and verify each cited source for high-stakes claims.
Change log
- — Initial publication. ASP data: Q2 2026 (J3590 priced via NOC / invoice; not in standard ASP layer). Lentiviral sister to Casgevy in the CareCost gene therapy catalog. Manufacturer source: bluebird Patient Services 2026. Five-way comparison vs Casgevy (CRISPR HSC), Zolgensma (J3399 AAV9), Hemgenix (J1411 AAV5 hemophilia B), and Roctavian (J1412 AAV5 hemophilia A). Multi-stage encounter (apheresis -> lentiviral transduction -> busulfan conditioning -> HSC infusion -> engraftment monitoring) documented. Boxed warning for hematologic malignancy + long-term follow-up REMS enrollment requirement documented. CMS CGT Access Model (active Jan 2025) referenced for participating state Medicaid programs.
Methodology
Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File and the OPPS Addendum B status indicator (where applicable; J3590 is NOC and Lyfgenia is commonly priced via invoice and the CMS CGT Access Model for participating state Medicaid). Payer policies are read directly from each payer's published medical/pharmacy policy documents. Indications, dosing, busulfan conditioning, boxed warning, and monitoring schedule are verified against the current FDA label revision. Outcomes-based contracting and CMS CGT Access Model context are verified against bluebird Patient Services operational guidance and CMS Innovation Center publications. We do not paraphrase from billing-software vendor blogs.